Back to news

Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference

Globe Newswire•17/11/2026•08:30 ET
1

Key Highlights

  • ➤Orchestra BioMed management to participate in Piper Sandler healthcare conference December 1-3, 2026
  • ➤David Hochman scheduled for fireside chat December 2, 2026, at 9:00am ET
  • ➤BACKBEAT Trial evaluating AVIM Therapy has completed enrollment
  • ➤Virtue Trial evaluating Virtue SAB for coronary in-stent restenosis is currently enrolling patients
  • ➤Orchestra BioMed collaborates with Medtronic on AVIM Therapy development and commercialization

Expert Statements

David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed

“Orchestra BioMed”

NEW HOPE, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, today announced that management will participate in the Piper Sandler 38(th) Annual Healthcare Conference being held December 1-3, 2026, in New York City. David Hochman, Chairman and Chief Executive Officer, will participate in a fireside chat hosted by Matthew O’Brien, Managing Director, Senior Research Analyst at Piper Sandler on Wednesday, Dec. 2, 2026, at 9:00am ET. Management will also host one-on-one meetings with investors during the event.

A live webcast of the event will be accessible through Orchestra BioMed’s Investor Relations website and will be available for replay following the event.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in